LDN-57444
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510324

CAS#: 668467-91-2

Description: LDN-57444 is a Uch-L1 inhibitor ( ubiquitin C-terminal hydrolase-L1) with Ki= 0.4 μ M. Ubiquitin carboxy-terminal hydrolase L1 ( UCH-L1 ) is an intracellular protein abundantly expressed in neurons, and a mutation in UCH-L1 has been identified in familial Parkinson's disease.


Price and Availability

Size Price Shipping out time Quantity
10mg USD 90 Same day
25mg USD 150 Same day
50mg USD 250 Same day
100mg USD 450 Same day
200mg USD 650 Same day
500mg USD 1350 Same day
1g USD 2050 Same day
2g USD 2950 2 Weeks
5g USD 4250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-25. Prices are subject to change without notice.

LDN-57444, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 510324
Name: LDN-57444
CAS#: 668467-91-2
Chemical Formula: C17H11Cl3N2O3
Exact Mass: 395.9835
Molecular Weight: 397.64
Elemental Analysis: C, 51.35; H, 2.79; Cl, 26.75; N, 7.04; O, 12.07


Synonym: LDN57444; LDN 57444; LDN-57444.

IUPAC/Chemical Name: (Z)-3-(acetoxyimino)-5-chloro-1-(2,5-dichlorobenzyl)indolin-2-one.

InChi Key: OPQRFPHLZZPCCH-PGMHBOJBSA-N

InChi Code: InChI=1S/C17H11Cl3N2O3/c1-9(23)25-21-16-13-7-12(19)3-5-15(13)22(17(16)24)8-10-6-11(18)2-4-14(10)20/h2-7H,8H2,1H3/b21-16-

SMILES Code: O=C1N(CC2=CC(Cl)=CC=C2Cl)C3=C(C=C(Cl)C=C3)/C1=N/OC(C)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information


References

1: Sankiewicz A, Laudanski P, Romanowicz L, Hermanowicz A, Roszkowska-Jakimiec W, Debek W, Gorodkiewicz E. Development of surface plasmon resonance imaging biosensors for detection of ubiquitin carboxyl-terminal hydrolase L1. Anal Biochem. 2015 Jan 15;469:4-11. doi: 10.1016/j.ab.2014.09.021. Epub 2014 Oct 13. PubMed PMID: 25312468.

2: Powis RA, Mutsaers CA, Wishart TM, Hunter G, Wirth B, Gillingwater TH. Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target. Neuropathol Appl Neurobiol. 2014 Dec;40(7):873-87. doi: 10.1111/nan.12168. PubMed PMID: 25041530.

3: Xie M, Wang SH, Lu ZM, Pan Y, Chen QC, Liao XM. UCH-L1 inhibition involved in CREB dephosphorylation in hippocampal slices. J Mol Neurosci. 2014 May;53(1):59-68. doi: 10.1007/s12031-013-0197-z. Epub 2013 Dec 10. PubMed PMID: 24323362.

4: Martínez-Villarreal J, García Tardón N, Ibáñez I, Giménez C, Zafra F. Cell surface turnover of the glutamate transporter GLT-1 is mediated by ubiquitination/deubiquitination. Glia. 2012 Sep;60(9):1356-65. doi: 10.1002/glia.22354. Epub 2012 May 16. PubMed PMID: 22593014.

5: Zhang M, Deng Y, Luo Y, Zhang S, Zou H, Cai F, Wada K, Song W. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem. 2012 Mar;120(6):1129-38. doi: 10.1111/j.1471-4159.2011.07644.x. Epub 2012 Feb 10. PubMed PMID: 22212137.

6: White RR, Miyata S, Papa E, Spooner E, Gounaris K, Selkirk ME, Artavanis-Tsakonas K. Characterisation of the Trichinella spiralis deubiquitinating enzyme, TsUCH37, an evolutionarily conserved proteasome interaction partner. PLoS Negl Trop Dis. 2011 Oct;5(10):e1340. doi: 10.1371/journal.pntd.0001340. Epub 2011 Oct 4. PubMed PMID: 22013496; PubMed Central PMCID: PMC3186758.

7: Hsu SH, Lai MC, Er TK, Yang SN, Hung CH, Tsai HH, Lin YC, Chang JG, Lo YC, Jong YJ. Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts. Clin Chim Acta. 2010 Dec 14;411(23-24):1920-8. doi: 10.1016/j.cca.2010.07.035. Epub 2010 Aug 14. PubMed PMID: 20713032.

8: Cartier AE, Djakovic SN, Salehi A, Wilson SM, Masliah E, Patrick GN. Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J Neurosci. 2009 Jun 17;29(24):7857-68. doi: 10.1523/JNEUROSCI.1817-09.2009. PubMed PMID: 19535597; PubMed Central PMCID: PMC2748938.

9: Tan YY, Zhou HY, Wang ZQ, Chen SD. Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor. Mol Cell Biochem. 2008 Nov;318(1-2):109-15. doi: 10.1007/s11010-008-9862-x. Epub 2008 Jul 12. PubMed PMID: 18622688.

10: Susor A, Ellederova Z, Jelinkova L, Halada P, Kavan D, Kubelka M, Kovarova H. Proteomic analysis of porcine oocytes during in vitro maturation reveals essential role for the ubiquitin C-terminal hydrolase-L1. Reproduction. 2007 Oct;134(4):559-68. PubMed PMID: 17890291.